TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17952272
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (G1)
Study: 17952272
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (G2)
Study: 11092514
Drug: Wine consumption
Normalized name: Wine grape
DrugBank: Wine grape (DB10634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wine consumption (190 mL red wine, 13% vol/vol ethanol, 5 days per week for 10 weeks)
Study: 3893139
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% epinephrine applied twice daily for two weeks
Study: 3893139
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin 25 mg four times daily for one week
Study: 3893139
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of indomethacin treatment in patients receiving topical epinephrine
Study: 31025894
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (1.5 g/day)
Study: 20865676
Drug: L-arginine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (8 g/day in two doses for 60 days)
Study: 20865676
Drug: Citrulline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline (3 g/day in one dose for 60 days)
Study: 15871849
Drug: Simvastatin 20mg
Normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20mg daily (S)
Study: 15871849
Drug: Fenofibrate 200mg
Normalized name: FENOFIBRATE 200MG CAP
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 200mg daily (F)
Study: 10815407
Drug: Early decision
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early decision making in surgery and physical/occupational therapy
Study: 10815407
Drug: More well-defined
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More well-defined indication for surgery considering trauma type, biological age, and functional demands
Study: 1950028
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg bid for 3 months
Study: 1950028
Drug: No antiulcer
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiulcer therapy for 3 months
Study: 1950028
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg bid for 6 months
Study: 1950028
Drug: No antiulcer
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiulcer therapy for 6 months
Study: 29954354
Drug: Ulva L.L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulva L.L. extract
Study: 25304934
Drug: Segmental epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segmental epidural steroid injections (SESIs)
Study: 22552602
Drug: Quadrivalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent meningococcal conjugate vaccine (MCV4) in PSV-exposed group (n = 145)
Study: 22552602
Drug: Meningococcal polysaccharide
Normalized name: meningococcal polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal polysaccharide vaccine (MPSV4) in PSV-exposed group (n = 142)
Study: 22552602
Drug: Quadrivalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent meningococcal conjugate vaccine (MCV4) in PSV-naïve group (n = 163)
Study: 20377413
Drug: 162 mg
Normalized name: aspirin 162 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 162 mg PRO 140 weekly
Study: 20377413
Drug: 324 mg
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 324 mg PRO 140 biweekly
Study: 20377413
Drug: 324 mg
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 324 mg PRO 140 weekly
Study: 15944071
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at acu‐points ST36, LI11, SP10, and GV14
Study: 15944071
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture (placebo) treatment
Study: 8708726
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with etoposide (120 mg/m2 on days 1 and 3) and vindesine (3 mg/m2 on day 3)
Study: 8708726
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with ifosfamide, etoposide, and an anthracycline (doxorubicin or epirubicin)
Study: 26729381
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to weekly cardiac rehabilitation (CR) exercise classes and information sessions.
Study: 21173294
Drug: 6 mL/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL/kg/h of crystalloid (restrictive fluid strategy)
Study: 21173294
Drug: 12 mL/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mL/kg/h of crystalloid (conservative fluid strategy)
Study: 16278262
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral vitamin D doses of 1,400 IU (200 IU/d)
Study: 16278262
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral vitamin D doses of 14,000 IU (2,000 IU/d)
Study: 14640932
Drug: Topical tazarotene
Normalized name: tazarotene Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene monotherapy
Study: 14640932
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies (with steroids, calcipotriene, and phototherapy)
Study: 11153016
Drug: SonoVue 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue 0.5 ml
Study: 11153016
Drug: SonoVue 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue 1 ml
Study: 11153016
Drug: SonoVue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue 2 ml
Study: 11153016
Drug: SonoVue 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue 4 ml
Study: 10436756
Drug: SonoVue (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue (all doses)
Study: 9160625
Drug: Pharmacotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy and psychotherapy
Study: 1423181
Drug: Metoclopramide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (1 mg/kg)
Study: 29608839
Drug: Sulodexide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide treatment for 50 days
Study: 23633757
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) combined with behavioral sleep strategies
Study: 23633757
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) combined with behavioral sleep strategies
Study: 12577369
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of composite Shendi Decoction (CSDD) and Diyin Tablet (DYT)
Study: 8029265
Drug: Tyrosine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine (150 mg/kg)
Study: 8029265
Drug: Tyrosine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine (150 mg/kg) at 22 degrees C
Study: 2557049
Drug: Tartar control
Normalized name: Aim Tartar Control Cool Mint Gel Toothpaste
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tartar control dentifrice formulation containing soluble pyrophosphates
Study: 16494632
Drug: Immediate PLLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate PLLA treatment
Study: 16494632
Drug: Delayed PLLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed PLLA treatment
Study: 11780993
Drug: Lidocaine-containing bioadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-containing bioadhesive patch (L-BP)
Study: 11780993
Drug: Benzocaine-containing gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine-containing gel (B-G)
Study: 11780993
Drug: Needlestick injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needlestick injections with anesthetic
Study: 9440907
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (0.15 IU/kg/day s.c.) for 1 year
Study: 8493626
Drug: Fenoterol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (400 micrograms) inhaled four times daily for 24 weeks
Study: 8493626
Drug: Placebo inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaled four times daily for 24 weeks
Study: 3371081
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (550 mg initial dose, then 275 mg as needed, max 5 doses/day for 3 days)
Study: 3371081
Drug: Dihydrocodeine tartrate
Normalized name: Dihydrocodeine tartrate
DrugBank: Dihydrocodeine (DB01551)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydrocodeine tartrate (30 mg initial dose, then 30 mg as needed, max 5 doses/day for 3 days)
Study: 22269534
Drug: 0.42 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42 mg/kg methamphetamine
Study: 20039172
Drug: Nebivolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (2.5 mg/day, uptitrated to 10 mg/day)
Study: 17362710
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (20 microg of ethinyl estradiol/100 mg of levonorgestrel)
Study: 12221216
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fructose fed 60 min before the potato meal
Study: 12221216
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fructose fed 30 min before the potato meal
Study: 12221216
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g available carbohydrate from instant mashed potatoes (control)
Study: 9706927
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (15 mg) with morphine sulfate (0.2 mg)
Study: 9706927
Drug: Hypobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric bupivacaine (15 mg) with morphine sulfate (0.2 mg)
Study: 8581394
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy with recombinant human GM-CSF (rhGM-CSF)
Study: 8581394
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of chemotherapy without rhGM-CSF
Study: 481976
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (50 mg/kg intramuscularly during days 1 to 3 of life)
Study: 27644475
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (PE) 1000 mg
Study: 26543359
Drug: Zabofloxacin (367
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zabofloxacin (367 mg once daily for 5 days)
Study: 21704212
Drug: Lifestyle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle therapy
Study: 1951300
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid administered pre-ECC
Study: 1951300
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid administered post-ECC
Study: 25133646
Drug: Whole-body cryotherapy
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryotherapy (WBC) twice a week
Study: 21166843
Drug: Diagnosis based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis based on two consecutive oral glucose tolerance tests
Study: 18058810
Drug: Topotecan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan with thalidomide (200 mg/day, increased as tolerated)
Study: 16925692
Drug: Budesonide/formoterol (80/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (80/4.5 microg, two inhalations twice daily)
Study: 16925692
Drug: Budesonide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (100 microg, two inhalations twice daily)
Study: 16925692
Drug: Budesonide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (100 microg, two inhalations twice daily) and formoterol (4.5 microg, two inhalations twice daily) in separate inhalers
Study: 12968985
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg intravenous bolus followed by 1.0 or 1.25 mg/kg subcutaneously twice a day)
Study: 1596501
Drug: Se-rich bread
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se-rich bread providing 100 micrograms Se daily for 6 weeks
Study: 1596501
Drug: Se-rich bread
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se-rich bread providing 200 micrograms Se daily for 6 weeks
Study: 1596501
Drug: Se-rich bread
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se-rich bread providing 300 micrograms Se daily for 6 weeks
Study: 3880521
Drug: Bepridil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (400 mg daily)
Study: 17148518
Drug: Constraint‐Induced Movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐Induced Movement Therapy plus donepezil (CIMT‐6 study)
Study: 17148518
Drug: Constraint‐Induced Movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐Induced Movement Therapy plus repetitive transcranial magnetic stimulation (CIMT‐1 study)
Study: 14569738
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg daily of vaginally administrated Cyclogest (progesterone) alone
Study: 14569738
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg daily of vaginally administrated Cyclogest (progesterone) in combination with 2 mg daily of oral Oestradiol Valerate (E2V)
Study: 14569738
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg daily of vaginally administrated Cyclogest (progesterone) with E2V
Study: 6813360
Drug: acebutolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (mean dose 913 mg/day) during single-blind phase
Study: 6813360
Drug: acebutolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (mean dose 968 mg/day) during double-blind phase
Study: 15698940
Drug: Calcium 1
Normalized name: Calcium 10-undecenoate
DrugBank: Calcium undecylenate (DB15678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1 g + Vitamin D 800 IU daily
Study: 12693587
Drug: Dihydroartemisinin 240
Normalized name: Succinyl dihydroartemisinin
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dihydroartemisinin 240 mg and mefloquine 1,250 mg given over 3 days (Group 1)
Study: 12693587
Drug: Dihydroartemisinin 240
Normalized name: Succinyl dihydroartemisinin
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dihydroartemisinin 240 mg and azithromycin 1,500 mg given over 3 days (Group 2)
Study: 2920667
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 ml of pure alcohol/kg body weight)
Study: 24839884
Drug: 1.3 grams
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 grams of omega-3 fatty acids daily for 6 weeks
Study: 24839884
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo daily for 6 weeks
Study: 17457340
Drug: Plant-based dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-based dietary portfolio (high in plant sterols 1.0 g/1000 kcal, soy protein 22.5 g/1000 kcal, viscous fibers 10 g/1000 kcal, almonds 22.5 g/1000 kcal)
Study: 10679756
Drug: 3-month neoadjuvant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month neoadjuvant LH-RH-analogue treatment
Study: 9275141
Drug: Aqueous wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous wheat flour extract inhalation at concentrations of 0.01, 0.1, 1, 10, and 100 mg/ml for 10 minutes.
Study: 9275141
Drug: Wheat flour
Normalized name: Wheat Flour
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat flour dust inhalation from Spinhaler capsules (1, 2, or 4 capsules, maximum of 7 cumulative capsules).
Study: 9275141
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (atopic subjects) inhaling wheat flour dust from capsules.
Study: 9275141
Drug: Both methods
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both methods (aqueous extract and dust inhalation).
Study: 3094919
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (Group E)
Study: 3094919
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (Group I)
Study: 31722820
Drug: Midazolam (buccal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (buccal, intranasal or intramuscular)
Study: 31722820
Drug: Lorazepam or
Normalized name: lorazepam Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam or Diazepam (IV agents)
Study: 16822101
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group treatment
Study: 10748773
Drug: Irrigation suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irrigation suction drainage (ISD) with 6000 ml of saline solution per day for 7 or more days
Study: 10748773
Drug: Irrigation suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irrigation suction drainage (ISD) with 2000 ml of saline solution per day
Study: 10748773
Drug: Irrigation suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irrigation suction drainage (ISD) with 6000 ml of saline solution per day
Study: 1915807
Drug: monthly 5
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monthly 5 day courses with thioguanine and cytarabine
Study: 7250173
Drug: Ibopamine hydrochloride
Normalized name: ibopamine hydrochloride
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine hydrochloride (SB 7505) at doses starting from 100 mg to 350 mg
Study: 28351163
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg/d
Study: 21944133
Drug: Tamsulosin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (various doses)
Study: 21944133
Drug: Tamsulosin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (low dose)
Study: 21944133
Drug: Tamsulosin (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (medium dose)
Study: 21944133
Drug: Tamsulosin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (high dose)
Study: 17090988
Drug: Yakson therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yakson therapy
Study: 16691043
Drug: GHT therapy
Normalized name: Systane Overnight Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHT therapy
Study: 17536290
Drug: Slow Sequential
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow Sequential Compression (SCD)
Study: 8629747
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine (0.2 mg/kg bolus followed by 0.5 mg/kg/hour infusion for 3 hours, adjusted to 0.1 mg/kg bolus for the first 9 patients)
Study: 8629747
Drug: Placebo (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (bolus and infusion for 3 hours)
Study: 6658721
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg given perorally three times a day for three months
Study: 25263242
Drug: HSS 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSS 3% with epinephrine (3 mL)
Study: 25263242
Drug: HSS 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSS 3% with placebo (3 mL)
Study: 25711836
Drug: Mesoglycan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan 50 mg twice daily for 90 days
Study: 16847549
Drug: 0.82 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.82 g/kg dose of alcohol
Study: 12742478
Drug: Sirolimus, cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus, cyclosporine microemulsion formulation, and prednisone
Study: 12742478
Drug: Sirolimus-based protocol
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus-based protocol with decreased calcineurin inhibitors
Study: 9107558
Drug: Euphytose (EUP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphytose (EUP) - two tablets three times a day over 28 days
Study: 9107558
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - two tablets three times a day over 28 days
Study: 30463831
Drug: Methyl carprost
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl carprost suppository combined with oxytocin
Study: 27248440
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (10 mg enalapril)
Study: 14660913
Drug: Topical ciprofloxacin/dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ciprofloxacin/dexamethasone
Study: 8063466
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (LC) group, 2 grams L-carnitine in a citrus drink twice daily for 7 days
Study: 2522729
Drug: Doxazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1 to 8 mg/day)
Study: 24373610
Drug: Aspirin (81mg/day)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (81mg/day) for 7 days